Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives

the European Child and Adolescent Clinical Psychopharmacology Network

Research output: Contribution to journalReview articlepeer-review

Abstract

Paediatric psychopharmacology holds great promise in two equally important areas of enormous biomedical and social impact, namely the treatment of behavioural abnormalities in children and adolescents, and the prevention of psychiatric disorders with adolescent- or adult-onset. Yet, in striking contrast, pharmacological treatment options presently available in child and adolescent psychiatry are dramatically limited. The most important currently unmet needs in paediatric psychopharmacology are: the frequent off-label prescription of medications to children and adolescents based exclusively on data from randomized controlled studies involving adult patients; the frequent lack of age-specific dose, long-term efficacy and tolerability/safety data; the lack of effective medications for many paediatric psychiatric disorders, most critically autism spectrum disorder; the scarcity and limitations of randomized placebo-controlled trials in paediatric psychopharmacology; the unexplored potential for the prevention of psychiatric disorders with adolescent- and adult-onset; the current lack of biomarkers to predict treatment response and severe adverse effects; the need for better preclinical data to foster the successful development of novel drug therapies; and the effective dissemination of evidence-based treatments to the general public, to better inform patients and families of the benefits and risks of pharmacological interventions during development. Priorities and strategies are proposed to overcome some of these limitations, including the European Child and Adolescent Clinical Psychopharmacology Network, as an overarching Pan-European infrastructure aimed at reliably carrying out much needed psychopharmacological trials in children and adolescents, in order to fill the identified gaps and improve overall outcomes.

Original languageEnglish (US)
Pages (from-to)1513-1531
Number of pages19
JournalEuropean Neuropsychopharmacology
Volume25
Issue number10
DOIs
StatePublished - Oct 2015

Keywords

  • Autism spectrum disorder
  • Biomarkers
  • Intellectual disability
  • Off-label use
  • Pharmaceutical policies
  • Psychopharmacology

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives'. Together they form a unique fingerprint.

Cite this